Log in to add personal notes on this page.
Phenylalanine is an essential amino acid that the body converts to tyrosine, the precursor of dopamine, norepinephrine, adrenaline, melanin, and thyroid hormone. Tyrosine itself is then broken down in the liver to fumarate, which enters the Krebs cycle, and acetoacetate, a ketone body. A block at the first step starves tyrosine's products and floods the brain with phenylalanine; a block further down leaves a toxic intermediate behind.
- phenylalanine → tyrosine: phenylalanine hydroxylase (PAH), with tetrahydrobiopterin (BH4) as its cofactor. Blocked in phenylketonuria.
- tyrosine → 4-hydroxyphenylpyruvate: tyrosine aminotransferase (TAT), the first step of tyrosine breakdown.
- 4-hydroxyphenylpyruvate → homogentisic acid: 4-hydroxyphenylpyruvate dioxygenase. Nitisinone blocks this step on purpose.
- homogentisic acid → maleylacetoacetate: homogentisate 1,2-dioxygenase (HGD). Blocked in alkaptonuria.
- maleylacetoacetate → fumarylacetoacetate: maleylacetoacetate isomerase, the next step on the way down.
- fumarylacetoacetate → fumarate + acetoacetate: fumarylacetoacetate hydrolase (FAH), the last enzyme. Blocked in tyrosinemia type 1.
- Phenylketonuria: phenylalanine cannot become tyrosine. Phenylalanine and its by-products (phenylpyruvic, phenylacetic, and phenyllactic acids) accumulate and injure the developing brain; tyrosine and its products run short, and with tyrosinase also inhibited, skin and hair are lighter. Newborn screening measures phenylalanine and the phenylalanine to tyrosine ratio.
- Alkaptonuria: homogentisic acid cannot be opened. It spills into urine, which darkens on standing, and deposits as pigment in cartilage (ochronosis), causing arthritis of the spine and large joints in adulthood. The lab marker is urine homogentisic acid.
- Tyrosinemia type 1: the last step fails, so fumarylacetoacetate builds up in liver cells and is diverted to succinylacetone. The result is liver failure, a high risk of hepatocellular carcinoma, renal tubular dysfunction, and porphyria-like neurologic crises. Succinylacetone in blood or urine is the diagnostic marker; tyrosine rises only secondarily.
- Also on this pathway, without a page here yet: tyrosinemia type II from TAT (tyrosine itself accumulates: corneal dystrophy, painful hyperkeratosis of the palms and soles, variable intellectual disability) and the BH4 synthesis and recycling defects, which raise phenylalanine like PKU.
- Phenylalanine high, tyrosine low places the block at step 1. Every baby with persistent high phenylalanine is also tested for a BH4 defect, because BH4 is the cofactor for tyrosine and tryptophan hydroxylation too: those babies need BH4 and neurotransmitter precursors, not diet alone.
- Succinylacetone is specific to tyrosinemia type 1. A high tyrosine without it points elsewhere: transient tyrosinemia of the newborn, tyrosinemia type II or III, or liver disease from another cause.
- Urine homogentisic acid is specific to alkaptonuria.
- Nitisinone treats both tyrosinemia type 1 and alkaptonuria because it blocks step 3, upstream of both blocks; the price is a higher tyrosine, which is why treatment of tyrosinemia type 1 adds a diet low in tyrosine and phenylalanine.